Among the breast cancer molecular subtypes, triple negative breast cancer (TNBC), accounting for 15–20% of all breast cancers, is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (Her-2) expression (1). Here, ERBB2 is linked to triple-negative breast carcinoma.